The IMID Forum

← The IMID Forum30 Sept · 20 min

Discussing axSpA: 52-week results from the Phase 3 BE MOBILE trials

Discussing axSpA: 52-week results from the Phase 3 BE MOBILE trials30 Sept20 min
Listen on SpotifyAlso works in your browser
11 more apps

Join Dr Sofia Ramiro and Dr Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered whether men and women with axSpA respond differently to bimekizumab, using 52-week data from the BE MOBILE 1 and 2 trials, covering both non-radiographic and radiographic axSpA.